Bausch + Lomb ($BLCO) Stock Forecast: Up 9.6% Today

What is Bausch + Lomb?

Bausch + Lomb (BLCO) is a renowned eye health company known for its contact lenses and eye care products. The stock had a significant bullish movement today amidst market fluctuations.

Why is Bausch + Lomb going up?

BLCO stock is up 9.6% on Sep 18, 2024 16:40

• BLCO shares surged by 14.5% in the last trading session, indicating strong investor interest and positive market sentiment.
• Speculation circulates that Bausch + Lomb is contemplating a sale as part of its efforts to address separation challenges from its parent company, Bausch Health Companies. This possibility may have sparked optimism among investors regarding potential strategic moves and value unlocking.
• The company's stock performance was also influenced by the FDA communication that an advisory committee meeting would no longer be required for Applied Therapeutics, Inc. (APLT), which could have had a positive spillover effect on related healthcare stocks like BLCO.
• Despite the recent surge, it's essential to note that the latest trend in earnings estimate revisions for BLCO does not suggest further strength down the road, indicating a need for cautious optimism among investors.

BLCO Price Chart

BLCO Technical Analysis

BLCO News

Applied Therapeutics, PowerFleet, VF Corp, Victoria's Secret And Other Big Stocks Moving Higher On Wednesday - Applied Therapeutics ( NASDAQ:APLT )

U.S. stocks were mixed, with the Dow Jones index falling around 0.2% on Wednesday. Shares of Applied Therapeutics, Inc. APLT rose sharply during Wednesday's session after the FDA communicated that an advisory committee meeting would no longer be required.

https://www.benzinga.com/news/24/09/40920347/applied-therapeutics-powerfleet-vf-corp-victorias-secret-and-other-big-stocks-moving-higher-on-wedne

Bausch + Lomb Surges 14.5%: Is This an Indication of Further Gains? - Alignment Healthcare ( NASDAQ:ALHC ) , Bausch & Lomb ( NYSE:BLCO )

Bausch + Lomb BLCO shares ended the last trading session 14.5% higher at $17.80. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 2.8% loss over the past four weeks.

https://www.benzinga.com/news/earnings/24/09/40892935/bausch-lomb-surges-14-5-is-this-an-indication-of-further-gains

Op-ed: Here's why a sale of Bausch + Lomb could lead to a windfall for Bausch Health investors

Hedge fund managers sit on the boards of Bausch Health and Bausch + Lomb. They don't think like your typical corporate board, writes Ken Squire of 13D Monitor.

https://www.cnbc.com/2024/09/17/op-ed-sale-of-bausch-lomb-may-lead-to-windfall-for-bausch-health-investors.html

Bausch + Lomb ( BLCO ) Surges 14.5%: Is This an Indication of Further Gains?

Bausch + Lomb (BLCO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

https://www.zacks.com/stock/news/2336876/bausch-lomb-blco-surges-145-is-this-an-indication-of-further-gains

Contact Lens Supplier Bausch + Lomb Eyes Sale Amid Separation Challenges As Parent Bausch Health Faces Debt Issues - Bausch & Lomb ( NYSE:BLCO ) , Bausch Health Companies ( NYSE:BHC )

Bausch + Lomb Corp BLCO is reportedly considering a sale as it navigates separation issues from its parent company, Bausch Health Companies BHC. The potential sale is part of efforts to address concerns from creditors like Apollo Global Management Inc APO following disputes over the separation.

https://www.benzinga.com/news/large-cap/24/09/40884021/contact-lens-supplier-bausch-lomb-eyes-sale-amid-separation-challenges-as-parent-bausch-health-fac

Trending Today

Ethena ($ENA) Crypto Forecast: Up 22.8% Today

Chainlink ($LINK) Crypto Forecast: Down 5.0% Today

Wormhole ($W) Crypto Forecast: Up 5.9% Today

Avalanche ($AVAX) Crypto Forecast: Down 7.3% Today

Arbitrum ($ARB) Crypto Forecast: Down 5.3% Today

Shiba Inu ($SHIB) Crypto Forecast: Down 5.1% Today

Aave ($AAVE) Crypto Forecast: Down 5.3% Today

Filecoin ($FIL) Crypto Forecast: Down 5.3% Today

Litecoin ($LTC) Crypto Forecast: Down 5.5% Today

TRON ($TRX) Crypto Forecast: Down 5.0% Today

Bausch + Lomb Price History

18.08.2024 - BLCO Stock was up 14.3%

• BLCO stock surged 14.5% in the last trading session, reaching $17.80, with a significant increase in trading volume.
• Speculation around a potential sale of Bausch + Lomb is circulating, which could lead to a windfall for Bausch Health investors, as suggested by hedge fund managers.
• The surge in BLCO's stock price could be attributed to the news of a possible sale, which is seen as a strategic move to address separation challenges from its parent company, Bausch Health Companies.
• Investors are optimistic about the future potential gains for BLCO, as indicated by the recent strong bullish movement and the ongoing discussions regarding the company's restructuring efforts.

18.08.2024 - BLCO Stock was up 9.6%

• BLCO shares surged by 14.5% in the last trading session, indicating strong investor interest and positive market sentiment.
• Speculation circulates that Bausch + Lomb is contemplating a sale as part of its efforts to address separation challenges from its parent company, Bausch Health Companies. This possibility may have sparked optimism among investors regarding potential strategic moves and value unlocking.
• The company's stock performance was also influenced by the FDA communication that an advisory committee meeting would no longer be required for Applied Therapeutics, Inc. (APLT), which could have had a positive spillover effect on related healthcare stocks like BLCO.
• Despite the recent surge, it's essential to note that the latest trend in earnings estimate revisions for BLCO does not suggest further strength down the road, indicating a need for cautious optimism among investors.

13.01.2024 - BLCO Stock was down 5.1%

• The recent decline in BLCO's stock price could be attributed to its disappointing Q4 2023 financial results, which did not meet expectations.
• Market sentiment may have been influenced by discussions during recent company events, which may have raised concerns or highlighted potential issues.
• Investors may have responded to weaker than anticipated sales and EPS figures for Q4 2023, resulting in a sell-off of BLCO's stock.

21.01.2024 - BLCO Stock was up 13.5%

• BLCO stock experienced a bullish movement following the company's impressive fourth-quarter sales, with a revenue increase of 18% year-on-year.
• The positive earnings beat and revenue growth exceeding expectations set a bullish tone for investors, leading to a surge in the stock price.
• CEO Brent Saunders' optimistic outlook for 2024 further fueled investor confidence in the company's future performance, contributing to the stock's upward momentum.
• The appointment of former Bausch & Lomb executive Joseph Gordon by Water Street Healthcare Partners may have also generated positive sentiment around the company, reinforcing investor interest in BLCO stock.

12.08.2023 - BLCO Stock was up 7.0%

• The announcement of the proposed financing for the acquisition of XIIDRA by Bausch + Lomb could have sparked investor optimism and confidence in the company's growth prospects.
• The disclosure of historical and pro forma financial information related to the acquisition of XIIDRA might have provided positive insights into the potential synergies and future performance of Bausch + Lomb.
• The surge in trading volume during the session indicates increased investor interest and buying activity, suggesting a positive sentiment surrounding the stock.
• Overall, the bullish movement in BLCO could be attributed to the positive news surrounding the company's acquisition plans and the market's positive response to it.

21.01.2024 - BLCO Stock was up 13.8%

• BLCO stock soared after unveiling fourth-quarter sales that outperformed expectations by 18% year-over-year, particularly driven by strong growth in pharmaceutical revenues.
• The CEO's encouraging forecasts regarding revenue expansion in 2023 and 2024 bolstered investor confidence in the company's future performance.
• The recent appointment of a former Bausch & Lomb executive to a key position at Water Street Healthcare Partners is seen as a positive development for BLCO, signaling ongoing industry expertise and potential avenues for growth.

21.01.2024 - BLCO Stock was up 8.7%

• BLCO stock soared by 11% due to a recent earnings beat, showcasing strong financial performance that exceeded market expectations.
• The appointment of a former Bausch & Lomb executive by Water Street Healthcare Partners to focus on medical products investment opportunities likely boosted investor confidence in future growth prospects.
• Positive earnings reports from Toll Brothers, Exelon, and Garmin, combined with the general positive market sentiment, contributed to the upward movement of BLCO stock.
• Investor confidence in Bausch + Lomb's strategic direction and potential success in the eye health industry is growing, as evidenced by the market's response to these positive developments and strong financial results.

12.03.2024 - BLCO Stock was down 6.2%

• The comparison between BLCO and Avantor, Inc. might have highlighted potential weaknesses in BLCO's financials or growth prospects, leading to a sell-off by investors.
• Value investors may have shifted their focus towards AVTR, perceiving it as a better investment opportunity compared to BLCO.
• This shift in investor sentiment, coupled with any specific negative news or developments related to BLCO, could have contributed to the bearish movement in the stock today.

21.01.2024 - BLCO Stock was up 10.1%

• BLCO's stock experienced a strong bullish movement today, rising significantly.
• The surge in stock price can be attributed to the company's recent earnings beat, where revenue growth in 2023 exceeded expectations, setting a positive tone for 2024.
• The appointment of Joseph Gordon, a former Bausch & Lomb executive, by Water Street Healthcare Partners might have also contributed to investor confidence in the company's future prospects.
• Analysts and investors are optimistic about BLCO's performance, with projections and insights indicating a potential beat in its upcoming earnings report, further fueling the positive sentiment surrounding the stock.

22.01.2024 - BLCO Stock was up 8.0%

• BLCO stock surged following the announcement of better-than-expected earnings and revenue for the fourth quarter of 2023, accompanied by an 18% year-on-year sales increase.
• The company's positive performance was driven by a notable increase in pharmaceutical sales, surpassing profit and sales projections.
• CEO Brent Saunders' positive revenue growth outlook for 2023 and 2024 boosted investor confidence, resulting in an 11% increase in the stock price.
• Despite unusual options activity suggesting bearish sentiment towards Bausch Health Companies (BHC), BLCO continued on its upward trend as investors focused on the company's strong financial results and growth potential.

24.06.2024 - BLCO Stock was down 4.4%

• The bearish movement in BLCO's stock today could be attributed to analysts' estimates of a decline in earnings for the company.
• Investors might be reacting to the lack of positive indicators for a potential earnings beat in BLCO's upcoming report, leading to a sell-off of the stock.
• This news has likely influenced market sentiment towards BLCO, causing a significant downward movement in its stock price today.

02.07.2024 - BLCO Stock was down 5.6%

• Despite matching Q2 earnings estimates, the stock had a bearish movement, possibly disappointing investors who may have been anticipating stronger performance.
• The earnings report revealed a 0% surprise in earnings and a 4.11% revenue surprise, which could have contributed to investor disappointment over the lack of robust growth indicators.
• The unclear signals in the earnings report regarding future outlook may have left investors apprehensive about the company's prospects.
• Market sentiment towards BLCO may have been influenced by various factors beyond the earnings report, possibly including broader market conditions and industry trends.